SEPSIS: MULTIPLE ABNORMALITIES, HETEROGENEOUS RESPONSES, AND EVOLVING UNDERSTANDING

被引:311
作者
Iskander, Kendra N.
Osuchowski, Marcin F.
Stearns-Kurosawa, Deborah J.
Kurosawa, Shinichiro
Stepien, David
Valentine, Catherine
Remick, Daniel G.
机构
[1] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA
[3] AUVA, Ludwig Boltzmann Inst Expt & Clin Traumatol, Trauma Res Ctr, Vienna, Austria
基金
美国国家卫生研究院;
关键词
DISSEMINATED INTRAVASCULAR COAGULATION; C-REACTIVE PROTEIN; SYSTEMIC INFLAMMATORY RESPONSE; ENDOPLASMIC-RETICULUM-STRESS; CRITICALLY-ILL PATIENTS; ANTIGEN-DR EXPRESSION; NECROSIS-FACTOR-ALPHA; LIPOPOLYSACCHARIDE-BINDING PROTEIN; INTERLEUKIN-1 RECEPTOR ANTAGONIST; SOLUBLE HUMAN THROMBOMODULIN;
D O I
10.1152/physrev.00037.2012
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Sepsis represents the host's systemic inflammatory response to a severe infection. It causes substantial human morbidity resulting in hundreds of thousands of deaths each year. Despite decades of intense research, the basic mechanisms still remain elusive. In either experimental animal models of sepsis or human patients, there are substantial physiological changes, many of which may result in subsequent organ injury. Variations in age, gender, and medical comorbidities including diabetes and renal failure create additional complexity that influence the outcomes in septic patients. Specific system-based alterations, such as the coagulopathy observed in sepsis, offer both potential insight and possible therapeutic targets. Intracellular stress induces changes in the endoplasmic reticulum yielding misfolded proteins that contribute to the underlying pathophysiological changes. With these multiple changes it is difficult to precisely classify an individual's response in sepsis as proinflammatory or immunosuppressed. This heterogeneity also may explain why most therapeutic interventions have not improved survival. Given the complexity of sepsis, biomarkers and mathematical models offer potential guidance once they have been carefully validated. This review discusses each of these important factors to provide a framework for understanding the complex and current challenges of managing the septic patient. Clinical trial failures and the therapeutic interventions that have proven successful are also discussed.
引用
收藏
页码:1247 / 1288
页数:42
相关论文
共 449 条
  • [1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [2] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, E
    Laterre, P
    Garg, R
    Levy, H
    Talwar, D
    Trzaskoma, BL
    Francois, B
    Guy, JS
    Bruckmann, M
    Rea-Neto, A
    Rossaint, R
    Perrotin, D
    Sablotzki, A
    Arkins, N
    Utterback, BG
    Macias, WL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) : 1332 - 1341
  • [3] p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial
    Abraham, E
    Glauser, MP
    Butler, T
    Garbino, J
    Gelmont, D
    Laterre, PF
    Kudsk, K
    Bruining, HA
    Otto, C
    Tobin, E
    Zwingelstein, C
    Lesslauer, W
    Leighton, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19): : 1531 - 1538
  • [4] Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients
    Adib-Conquy, Minou
    Adrie, Christophe
    Fitting, Catherine
    Gattolliat, Olivier
    Beyaert, Rudi
    Cavaillon, Jean-Marc
    [J]. CRITICAL CARE MEDICINE, 2006, 34 (09) : 2377 - 2385
  • [5] Influence of gender on the outcome of severe sepsis - A reappraisal
    Adrie, Christophe
    Azoulay, Elie
    Francais, Adrien
    Clec'h, Christophe
    Darques, Loic
    Schwebel, Carole
    Nakache, Didier
    Jamali, Samir
    Goldgran-Toledano, Dany
    Garrouste-Orgeas, Maite
    Timsit, Jean Francois
    [J]. CHEST, 2007, 132 (06) : 1786 - 1793
  • [6] Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis
    Afshari, Arash
    Wetterslev, Jorn
    Brok, Jesper
    Moller, Ann
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2007, 335 (7632): : 1248 - 1251
  • [7] ALEXANDER HR, 1991, J SURG RES, V50, P421
  • [8] New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores
    Angstwurm, MWA
    Dempfle, CE
    Spannagl, M
    [J]. CRITICAL CARE MEDICINE, 2006, 34 (02) : 314 - 320
  • [9] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [10] E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis - A randomized controlled trial
    Angus, DC
    Birmingham, MC
    Balk, RA
    Scannon, PJ
    Collins, D
    Kruse, JA
    Graham, DR
    Dedhia, HV
    Homann, S
    MacIntyre, N
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13): : 1723 - 1730